Clare Byrne
Research Subjects
Research Interests
Clare Byrne has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Amrita Sawhney
Novartis Pharmaceuticals Corporation, East Hanover, USA
2 shared publications - Barinder Kang
Novartis Pharmaceuticals Corporation, East Hanover, USA
2 shared publications - Chi-Chang Chen
IQVIA
2 shared publications - Jackson Tang
Asclepius Analytics LLC, New York, NY
2 shared publications - Jeetvan Patel
Novartis Pharmaceuticals Corporation, East Hanover, USA
2 shared publications - Jennifer Nguyen
Novartis Pharmaceuticals Corporation, East Hanover, USA
2 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (11) , 2835
Correction to: Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer
- 30 September 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (11) , 2835
Open AccessCorrection to: Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer
- Open Access
- 25 June 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (8) , 1451-1471
Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer
Background: Metastatic castration-resistant prostate cancer (mCRPC) treatment commonly includes first-line (1L) androgen receptor pathway inhibitors (ARPIs) followed by second-line (2L) taxane-based chemotherapy. Adverse events (AEs) may lead to early taxane discontinuation, which can negatively affect outcomes and costs. This retrospective observational study assessed real-world outcomes, AEs, and costs of 2L taxane therapy by number of cycles among patients with mCRPC previously treated with a 1L ARPI; outcomes were compared with patients receiving 2L ARPI. Methods: Overall survival (OS; overall and by number of taxane cycles received) was determined for 2L taxane and compared with 2L ARPI using the Flatiron Health electronic health record database (Jul 1, 2012, to Jun 30, 2020). Taxane-related AEs and associated costs were estimated using the IQVIA PharMetrics® Plus claims database (Jan 1, 2013, to Aug 31, 2021). Results: Overall, 2L ARPI ( n = 473) vs. taxane ( n = 214) was associated with longer median OS (15.4 vs. 13.6 months). Patients receiving > 8 ( n = 48) vs. ≤ 8 taxane cycles ( n = 166) had longer median OS (18.4 vs. 11.9 months; p = 0.006). Patients receiving > 8 vs. ≤ 8 taxane cycles were also more likely to experience an AE (95% vs. 88%) but had lower mean AE-related total healthcare costs per patient per month ($3,429 vs. $6,334). Conclusion: Patients who received > 8 cycles of 2L taxane had longer observed survival. However, these results are subject to selection bias and immortal time bias. Prospective or time-adjusted analyses are needed.
- 25 June 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 31 (8) , 1451-1471
Open AccessReal-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer
Background: Metastatic castration-resistant prostate cancer (mCRPC) treatment commonly includes first-line (1L) androgen receptor pathway inhibitors (ARPIs) followed by second-line (2L) taxane-based chemotherapy. Adverse events (AEs) may lead to early taxane discontinuation, which can negatively affect outcomes and costs. This retrospective observational study assessed real-world outcomes, AEs, and costs of 2L taxane therapy by number of cycles among patients with mCRPC previously treated with a 1L ARPI; outcomes were compared with patients receiving 2L ARPI. Methods: Overall survival (OS; overall and by number of taxane cycles received) was determined for 2L taxane and compared with 2L ARPI using the Flatiron Health electronic health record database (Jul 1, 2012, to Jun 30, 2020). Taxane-related AEs and associated costs were estimated using the IQVIA PharMetrics® Plus claims database (Jan 1, 2013, to Aug 31, 2021). Results: Overall, 2L ARPI ( n = 473) vs. taxane ( n = 214) was associated with longer median OS (15.4 vs. 13.6 months). Patients receiving > 8 ( n = 48) vs. ≤ 8 taxane cycles ( n = 166) had longer median OS (18.4 vs. 11.9 months; p = 0.006). Patients receiving > 8 vs. ≤ 8 taxane cycles were also more likely to experience an AE (95% vs. 88%) but had lower mean AE-related total healthcare costs per patient per month ($3,429 vs. $6,334). Conclusion: Patients who received > 8 cycles of 2L taxane had longer observed survival. However, these results are subject to selection bias and immortal time bias. Prospective or time-adjusted analyses are needed.